Intellectual Property

Bioneer/siRNAgen Therapeutics Corporation owns a portfolio of patents and patent applications related to SAMiRNA™ technology, RNAi drugs/molecules for particular disease indications. siRNAgen Therapeutics Corporation’s SAMiRNA™ core technology and drug pipeline are protected within an extensive global intellectual property portfolio comprised of more than 90 patent applications and issued patents.

Patent

Title Country Filing date Application No. Date of Patent Patent No.
siRNA conjugate and preparation method thereof KR 2009-05-14 10-2009-042297 2013-01-16 1224828
US 2010-05-13 13/319,885 2014-07-15 8779114
Novel oligonucleotide conjugates and use thereof PCT 2012-12-14 PCT/KR2012/010967
High-efficiency nanoparticle-type double-helical oligo-RNA structure and method for preparing same KR 2013-01-04 10-2014-7018685 2017-06-26 1752812
US 2013-01-04 14/370,035 2016-05-03 9326941
Magnetic nanoparticle-samirna complex and method for preparing same KR 2013-01-17 10-2013-0005335 2016-06-03 1629233
US 2013-01-17 14/372,211 2017-05-16 9649388
Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same KR 2014-07-04 10-2016-7001869 2018-05-23 1862349
US 2014-07-04 14/902,563 2018-07-24 10030243
Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease KR 2014-07-04 10-2016-7002234 2018-06-07 1867414
EP 2019-06-13 19180054.9 2019-10-16 3018209
Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases US 2015-04-06 15/301,713 2019-02-19 10208309
A double stranded oligonucleotide comprising Amphiregulin specific sequence and a composition for treating and preventing fibrosis related diseases and respiratory related diseases PCT 2019-05-22 PCT/KR2019/006144

Publication